Funded Biotechnology Startups in Austin
Austin's biotechnology funding record across the 24 most recent rounds spans from August 2020 through August 2025, with the most concentrated recent activi…
Austin's biotechnology funding record across the 24 most recent rounds spans from August 2020 through August 2025, with the most concentrated recent activity coming in the summer of 2025: Pattern Bioscience ($44M), Maxwell Biosciences ($20M), and Shattuck Labs ($103M) all closed within the first three weeks of August 2025. Earlier 2025 activity included a $19M Series A for neural prosthetics company Phantom Neuro and a $13M Series A for bioprocess software firm QbDVision. Disclosed round sizes across the dataset range from EQO's $100K Pre-Seed to Elligo Health Research's $135M Series E (September 2021).
The cohort reflects a broad definition of biotechnology — neural interface hardware, laboratory informatics (L7 Informatics, Vuv Analytics), clinical research services (Elligo Health Research), pharmaceutical formulation (TFF Pharmaceuticals, Plus Therapeutics), and oncology immunology (Shattuck Labs, Triumvira Immunologics, Genprex) all appear alongside earlier-stage diagnostics and genomics plays. Round structures are similarly varied, including a $18M federal grant to Plus Therapeutics in 2022 and a $65M Post-IPO Equity raise by Apollo Endosurgery in October 2021.
Most recent rounds
24 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Austin biotech companies in this data?
Elligo Health Research leads with a $135M Series E closed in September 2021, followed by Shattuck Labs at $103M (Series Unknown, August 2025) and Apollo Endosurgery at $65M via Post-IPO Equity in October 2021. Triumvira Immunologics ($55M), Cassava Sciences ($47M), and Trace ($47M) round out the top tier of disclosed raises.
How recent is the funding activity — are Austin biotech companies still closing rounds in 2025?
Three rounds closed in the first three weeks of August 2025: Pattern Bioscience ($44M), Maxwell Biosciences ($20M), and Shattuck Labs ($103M). Earlier in 2025, QbDVision raised a $13M Series A in May and Phantom Neuro closed a $19M Series A in April, placing five rounds within the first eight months of 2025.
What sub-sectors does Austin biotech funding cover beyond traditional drug development?
The data includes neural interface hardware (Phantom Neuro, Paradromics), laboratory informatics and workflow software (L7 Informatics, Vuv Analytics), clinical trial site networks (Elligo Health Research), diagnostic instrumentation (Pattern Bioscience, Advanced Scanners), and drug formulation technology (TFF Pharmaceuticals). Oncology and immunology appear across multiple companies including Shattuck Labs, Genprex, and Triumvira Immunologics.
What round stages are represented, and is the mix skewed toward early or late stage?
Stages span the full spectrum — Pre-Seed (EQO, $100K) and Seed (Aperiam Bio, $9M) at the early end through Series A, C, and E at later stages, plus a Grant (Plus Therapeutics, $18M) and a Post-IPO Equity round (Apollo Endosurgery, $65M). A significant portion of rounds are labeled Series Unknown, indicating either undisclosed stages or non-traditional structures rather than a clear concentration at any single stage.
How many rounds have undisclosed amounts, and does that affect sizing estimates?
At least four rounds in the dataset list amounts as undisclosed: Paradromics (February 2025), Parhelia Biosciences (October 2023), TFF Pharmaceuticals (May 2023), and Wenzel Spine ($500K is disclosed but the round type is Venture - Series Unknown). Any aggregate sizing calculation from this data will undercount actual capital deployed into the Austin biotech cohort.
Are there any companies in the data that have reached post-IPO status?
Apollo Endosurgery raised $65M in Post-IPO Equity in October 2021, making it the only post-IPO entrant in the 24 rows shown. Its inclusion signals that public Austin biotech companies have continued accessing private capital markets after listing.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.